Salix Pharmaceuticals Appoints Bellamy Young as Spokesperson for Xifaxan Campaign

Salix Pharmaceuticals has announced award-winning actor Bellamy Young as the new spokesperson for their Xifaxan medication, the only FDA-approved treatment aimed at reducing the risk of overt hepatic encephalopathy (OHE) recurrence in adults. OHE is a serious complication of cirrhosis, leading to potential brain damage due to the liver's inability to filter toxins from the blood.

The company revealed that the initiative intends to enhance awareness and understanding of OHE, encouraging patients and caregivers to actively manage this condition. Alongside her personal connection to the disease—having witnessed her father battle OHE—Young's campaign will leverage her story across various platforms, including a 60-second TV spot and social media, to foster wider discussions about OHE and its impacts.

This partnership also marks a proactive step by Salix Pharmaceuticals towards driving an informed discourse on OHE management among healthcare professionals, patients, and caregivers, ultimately aiming to foster better patient outcomes in managing cirrhosis complications.